ライフサイエンスコーパス: LHRH

1 LHRH agonists provide an additional class of agents for

2 LHRH agonists showed similar efficacy to chemotherapy (r

3 LHRH agonists were ineffective in hormone-receptor-negat

4 LHRH cell number after drug treatment as determined by i

5 LHRH cells exhibit neurophilic migration moving from the

6 LHRH mRNA levels were examined in young and middle-aged

7 LHRH mRNA levels were measured in cytosolic extracts, an

8 LHRH patients assessed their overall health as fair or p

9 LHRH patients reported more breast swelling than did orc

10 LHRH patients reported more physical discomfort and worr

11 LHRH receptors are expressed in a very high percentage o

12 LHRH-conjugated nanocapsules selectively delivered recom

13 LHRH-negative neurons in culture exhibited only occasion

14 LHRH-R mRNA expression in female pituitaries was reduced

15 In 20 cultures, 572 LHRH-positive cells exhibited [Ca(2+)](i) oscillations a

16 e not known to self-aggregate (amylin, ACTH, LHRH, angiotensin II, atrial natriuretic peptide, somato

17 e c-Fos expression in both SCN and activated LHRH neurons, with the percentage of LHRH+/c-Fos+ double

18 All LHRH mRNA positive neurons present in 4 anatomically mat

19 ng an l-GnRH-III polyclonal antiserum and an LHRH monoclonal antiserum.

20 No trials had assessed an LHRH agonist versus chemotherapy with tamoxifen in both

21 onal pseudorabies virus into the brain of an LHRH::CRE mouse line led to the identification of neuron

22 received either placebo (24 subjects) or an LHRH agonist (26 subjects).

23 Treatment with an LHRH agonist for 3.5 years increases adult height by 0.6

24 trial to determine whether treatment with an LHRH agonist increases adult height in short adolescents

25 Treatment with an LHRH agonist resulted in significantly greater adult hei

26 Survival after therapy with an LHRH agonist was equivalent to that after orchiectomy.

27 d, the subjects who had been treated with an LHRH agonist were older than those who had received plac

28 -R mRNA expression in female rats by 23% and LHRH-R protein levels by 119%.

29 nd diminished LHRH-R mRNA to 30% and 26% and LHRH-R protein to 57% and 48% on days 10 and 30, respect

30 pment, including olfactory sensory cells and LHRH cells.

31 lly, we showed that Mn2+ stimulated cGMP and LHRH from the same tissues, and that downstream blocking

32 els were measured in cytosolic extracts, and LHRH primary transcript levels were measured in nuclear

33 d and perfused for localization of c-Fos and LHRH, PRs alone, or c-Fos and PRs.

34 suppress pituitary gonadotroph functions and LHRH-receptor (LHRH-R) expression are incompletely under

35 Preclinical studies revealed that GHRH and LHRH antagonists both can cause a reduction in prostate

36 Pituitary LHRH-R mRNA and LHRH-R protein levels were not significantly different f

37 elix on serum LH, pituitary LHRH-R mRNA, and LHRH-R protein was greater than that of Decapeptyl.

38 itary sites, the interactions of the NPY and LHRH systems may involve diencephalic loci.

39 The overlap between the NPY and LHRH systems was apparent in the periventricular, parave

40 vealed dual expression of nestin protein and LHRH in cells proximal to the vomeronasal organ anlage t

41 ownregulated beginning at E12, so few if any LHRH neurons in the forebrain also express DCC.

42 in Locke solution for 30 min to assess basal LHRH secretion, then incubated with buffer alone or buff

43 the respective adhesive interactions between LHRH molecular recognition units on the prodigiosin (PGS

44 gonadotropin release in the presence of both LHRH and AA, whereas sodium nitroprusside, a releaser of

45 bypassed the surge in sex steroids caused by LHRH agonists, the gold standard for clinical ablation o

46 A rapid suppression of serum LH by LHRH antagonists would be advantageous in the treatment

47 idase E.C.3.4.24.15 (EP24.15), which cleaves LHRH at the Tyr5-Gly6 position.

48 metastatic hormone-sensitive PCa commencing LHRH +/- bicalutamide (cohort 1) and 7 men with castrate

49 These extrahypothalamic neurons contain LHRH fragments, rather than fully mature mammalian LHRH.

50 (LHRH) release, we examined whether cultured LHRH neurons exhibit spontaneous intracellular Ca(2+) ([

51 sed for targeted chemotherapy with cytotoxic LHRH analogue AN-207.

52 was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and c

53 The 3-monthly depot LHRH-agonist leuprorelin acetate is an effective adjuvan

54 The descladinose LHRH antagonist 14 has 1-2 nM affinity for both rat and

55 duced serum LH in female rats and diminished LHRH-R mRNA to 30% and 26% and LHRH-R protein to 57% and

56 Injections of LHRH-conjugated drugs (LHRH-prodigiosin or LHRH-paclitaxel) into groups of 4-we

57 Elevated LHRH-R protein levels of ovariectomized rats were reduce

58 ng 100 microg of peptide daily, the elevated LHRH-R mRNA level was decreased by 73%, whereas daily in

59 Embryonic LHRH neurons were examined in vivo for Mash-1 and nestin

60 heterozygous deletion in the nasal embryonic LHRH factor (NELF) gene in pedigree 1 and an additional

61 ion of a novel factor termed nasal embryonic LHRH factor (NELF) that was discovered in a differential

62 trical activity, also significantly enhanced LHRH migration.

63 but it did not block the nerve-firing-evoked LHRH release.

64 Moreover, nicotine evoked LHRH release when [Ca2+] elevation in the terminals was

65 We therefore examined LHRH neuron migration in DCC(-/-) mice and found that tr

66 and its ability to counteract the exogenous LHRH and the agonist triptorelin in the regulation of th

67 n vomeronasal axons in the nose also express LHRH.

68 not Mash-1, was detected in early expressing LHRH cells in the vomeronasal organ anlage.

69 A few LHRH-IR neurons and fibers were scattered in the mamilla

70 Specifically, fewer LHRH mRNA positive neurons were detected at 18:00 h comp

71 onic stage before the migration of bona fide LHRH neurons, and is ultimately distributed in the extra

72 at embryonic days (E) 32-E36, are bona fide LHRH neurons.

73 imary tumors or metastases were examined for LHRH receptor expression by immunohistochemistry.

74 Combined immunohistochemistry for LHRH neurons and in situ hybridization for GABAA subunit

75 Cells were fixed and immunostained for LHRH and neuron-specific enolase.

76 The mRNA for LHRH receptors, receptor protein and binding sites for L

77 which is similar to the period observed for LHRH release, whereas in 5 of 17 cultures the less tight

78 tors, receptor protein and binding sites for LHRH were detected in both transplantable melanoma tumor

79 cimens examined showed positive staining for LHRH receptors.

80 to identify neurons that synapse with GnRH (LHRH) neurons, the key regulators of reproduction.

81 es of luteinizing hormone-releasing hormone (LHRH) -like neurons, "early" and "late" cells, were disc

82 f the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl (25 microg/day) for 30 days or

83 ith a luteinizing hormone-releasing hormone (LHRH) agonist increases adult height in children with LH

84 lamic luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6]LHRH.

85 with luteinizing hormone-releasing hormone (LHRH) agonists is an effective adjuvant treatment for pr

86 with luteinising-hormone-releasing hormone (LHRH) agonists, but results have been inconclusive, espe

87 arin, leutinizing hormone releasing hormone (LHRH) and oligonucleotides, across the skin.

88 with luteinizing hormone-releasing hormone (LHRH) antagonist are also reviewed and analyzed.

89 luteinizing hormone (LH)-releasing hormone (LHRH) antagonists suppress pituitary gonadotroph functio

90 og of luteinizing hormone-releasing hormone (LHRH) as a targeting moiety specific to the receptors th

91 ed to Luteinizing Hormone-Releasing Hormone (LHRH) for the specific targeting and treatment of triple

92 Luteinizing hormone releasing hormone (LHRH) gene transcription was examined in ovariectomized

93 with Luteinizing Hormone-Releasing hormone (LHRH) ligands whose receptors are shown to overexpressed

94 o the luteinizing hormone-releasing hormone (LHRH) neuroendocrine phenotype are derived from the nasa

95 on of luteinizing hormone-releasing hormone (LHRH) neurons from the olfactory pit to the CNS.

96 Luteinizing hormone-releasing hormone (LHRH) neurons migrate from the olfactory placode to the

97 Luteinizing hormone-releasing hormone (LHRH) neurons migrate from the vomeronasal organ (VNO) t

98 lates luteinizing hormone releasing hormone (LHRH) neurons to secrete LHRH, the neuropeptide controll

99 Luteinizing hormone-releasing hormone (LHRH) neurosecretion, which regulates gonadal function,

100 ct of luteinizing hormone-releasing hormone (LHRH) on luteinizing hormone secretion in several specie

101 with luteinizing hormone-releasing hormone (LHRH) peptide via phospholipid, the fcc-FePt NPs can bin

102 ) and luteinizing hormone releasing hormone (LHRH) peptide, resulting in specific and efficient accum

103 ed by luteinizing hormone-releasing hormone (LHRH) receptor antagonism bypassed the surge in sex ster

104 ly inhibits stimulated LH-releasing hormone (LHRH) release from medial basal hypothalamic explants.

105 atile luteinizing hormone-releasing hormone (LHRH) release, we examined whether cultured LHRH neurons

106 ts of luteinizing hormone-releasing hormone (LHRH) release, which was monitored as slow membrane depo

107 duces luteinizing hormone-releasing hormone (LHRH) secretion from prepubertal female rats.

108 trols luteinizing hormone-releasing hormone (LHRH) secretion.

109 Luteinizing hormone-releasing hormone (LHRH) was used as a targeting moiety (ligand) to LHRH re

110 ue of luteinizing hormone releasing hormone (LHRH), AN-207, binds with high affinity to LHRH receptor

111 on of luteinizing hormone releasing hormone (LHRH), growth hormone releasing hexapeptide (GHRP-6), an

112 st of luteinizing hormone-releasing hormone (LHRH), reduces levels of serum LH, estradiol, progestero

113 on of luteinizing hormone-releasing hormone (LHRH), the neuropeptide controlling sexual development,

114 on of luteinizing hormone-releasing hormone (LHRH), the neuropeptide controlling sexual development.

115 erents from the SCN to LH releasing hormone (LHRH)-containing neurons in the preoptic area.

116 ptide luteinizing hormone-releasing hormone (LHRH).

117 ge in luteinizing hormone-releasing hormone (LHRH).

118 wn as luteinizing hormone releasing hormone (LHRH)] neurons can exhibit synchronized neuroendocrine s

119 izing luteinizing hormone-releasing hormone (LHRH, also known as gonadotropin-releasing hormone [GnRH

120 aive (luteinizing hormone-releasing hormone [LHRH] +/- bicalutamide) and in castrate-resistant men (e

121 lus a luteinizing hormone-releasing hormone [LHRH] agonist if premenopausal).

122 sion (luteinizing hormone-releasing hormone [LHRH] agonist), whereas 75 patients received radiation a

123 However, LHRH cell migration, as determined by the distance immun

124 4 has 1-2 nM affinity for both rat and human LHRH receptors and is a potent inhibitor of LH release (

125 t findings suggest that the hypophysiotropic LHRH-synthesizing neurons may be innervated by intrahypo

126 ctively, for patients who received immediate LHRH agonist versus 10% [corrected] and 4% for patients

127 onadectomized males evokes Fos activation in LHRH and AVPV neurons as it does in females.

128 Alterations in LHRH primary transcript levels preceded changes in level

129 ulating levels of LH, there was no change in LHRH immunoreactivity at any time.

130 onfirm earlier reports of dynamic changes in LHRH mRNA levels on the day of an LH surge.

131 onsistent with a role for dynamic changes in LHRH transcriptional activity in modulating parameters o

132 stent with a relative age-related decline in LHRH mRNA levels.

133 Moreover, the decrease in LHRH gene transcription during the ascending phase of th

134 These results were duplicated in LHRH neurons maintained in vitro in nasal explants.

135 e receptor subunits that may be expressed in LHRH neurons at this phase in development.

136 ut not the gamma 1 subunit, are expressed in LHRH neurons.

137 Prolonged nestin expression in LHRH cells after midline removal is consistent with nasa

138 een postulated that the pubertal increase in LHRH secretion in female animals also requires neuron-gl

139 This early activation did not occur in LHRH neurons.

140 In turn, the reduction in LHRH release is caused by the inability of hypothalamic

141 es of evidence that PSA-NCAM plays a role in LHRH cell migration: promotion of cell movement along th

142 dings suggest a potential role for increased LHRH gene transcription in the accumulation of LHRH prio

143 nicotine at very low concentrations induced LHRH release via a Na+-dependent, Ca2+-independent mecha

144 th KT5823 (10 microM) inhibited Mn2+-induced LHRH release.

145 and reversibly blocked the nicotine-induced LHRH release, but it did not block the nerve-firing-evok

146 d 250 microM MnCl2 all significantly induced LHRH release, the two lowest doses did not stimulate tot

147 NMMA also inhibited LHRH-induced LH and FSH release and gonadotropin release

148 iption-PCR analyses were used to investigate LHRH receptors in MRI-H255 and MRI-H187 transplantable h

149 udies suggested that both "early" and "late" LHRH cells expressed mammalian LHRH mRNA.

150 ian luteinizing hormone-releasing hormone (m-LHRH).

151 tantly, neurons that expressed l-GnRH-III, m-LHRH, or both peptides were also detected in the ventral

152 Immunopositive neurons for l-GnRH-III, m-LHRH, or neurons coexpressing both peptides were detecte

153 slightly dorsal to neurons containing only m-LHRH.

154 , but not by l-GnRH-I, chicken-GnRH-II, or m-LHRH.

155 The m-LHRH neurons were not observed in this area.

156 mone release but also are colocalized with m-LHRH neurons in areas primarily controlling LH release.

157 tes, a group of neurons containing mammalian LHRH mRNA arises at an early embryonic stage before the

158 y" and "late" LHRH cells expressed mammalian LHRH mRNA.

159 ragments, rather than fully mature mammalian LHRH.

160 Comparison of mammalian LHRH mRNA 3'-untranslated regions showed two conserved r

161 s are found in the basal forebrain, and many LHRH neurons are displaced into the cerebral cortex of D

162 CC function results in the migration of many LHRH neurons to inappropriate destinations.

163 essed on TAG-1(+) axons that guide migrating LHRH neurons.

164 M, and a preference of a subset of migrating LHRH cells for a PSA-positive axon branch over a PSA-neg

165 Whereas monthly LHRH agonist therapy has been well established, the valu

166 In mice, most LHRH neuron migration is dependent on axons that origina

167 sary for establishment of the neuroendocrine LHRH system, cells critical for reproductive function.

168 roglial erbB receptor activation on neuronal LHRH release.

169 data indicate that, in primary LHRH neurons, LHRH mRNA has an intrinsically high rate of turnover and

170 itary cells in vitro to 3-min pulses of 1 nM LHRH or 0.1 nM triptorelin for 5 h increased the LHRH-R

171 hylerythromycin A that are novel, nonpeptide LHRH antagonists, is described.

172 in male pituitaries to 58% on day 30 but not LHRH-R protein.

173 RH gene transcription in the accumulation of LHRH prior to the start of the LH surge and in the reple

174 blockade of the LH surge, both activation of LHRH and pePOA neurons was low or absent.

175 Addition of LHRH agonists to tamoxifen, chemotherapy, or both reduce

176 nd brains for immunocytochemical analysis of LHRH and c-fos.

177 neuraminidase N, followed by the analysis of LHRH cell positions, and examination of LHRH cell positi

178 the direct inhibitory action of GHRH and of LHRH antagonists exerted through prostatic receptors.

179 Blockade of LHRH receptors by an excess of LHRH agonist Decapeptyl s

180 en both AA and an effective concentration of LHRH were incubated together, there was no additive resp

181 n sites, the distribution and connections of LHRH and NPY-immunoreactive (IR) neuronal elements in th

182 reviously implicated in the glial control of LHRH secretion.

183 eatment time showed a rapid initial decay of LHRH mRNA (t1/2, 5-13 min), followed by a slower decay r

184 andidates for determining the destination of LHRH neurons.

185 idline tissues modulating differentiation of LHRH neurons from the nasal placode.

186 uently, we investigated the direct effect of LHRH antagonist cetrorelix in vitro on the expression of

187 ges, but prevented the stimulatory effect of LHRH pulses on the receptor mRNA expression.

188 , by counteracting the stimulatory effect of LHRH.

189 s of LHRH cell positions, and examination of LHRH cell positions in mutant mice deficient in the expr

190 Blockade of LHRH receptors by an excess of LHRH agonist Decapeptyl suppressed the effects of AN-207

191 We investigated the expression of LHRH receptors in surgical specimens of human malignant

192 The molecular form of LHRH in "early" cells differs from "late" cells, because

193 study, we investigated the molecular form of LHRH in the "early" cells in the nasal regions and brain

194 any specific antisera against known forms of LHRH.

195 -6, which cross-reacts with several forms of LHRH.

196 es employed indicate that only a fraction of LHRH neurons are endowed with GABAA receptors.

197 t effect observed was dramatic inhibition of LHRH cell migration in explants cultured in the presence

198 Injections of LHRH-conjugated drugs (LHRH-prodigiosin or LHRH-paclitax

199 The putative innervation of LHRH neurons by NPY-IR fibers was also seen in 1-microm-

200 ary LHRH receptor (LHRH-R) and the levels of LHRH-R protein were evaluated in rats.

201 indirectly, in the neurophilic migration of LHRH cells.

202 ns can have profound effects on migration of LHRH neurons and suggests that GABA participates in appr

203 t outgrowth of olfactory axons, migration of LHRH neurons in association with a subset of these axons

204 omeronasal axons that guide the migration of LHRH neurons.

205 Accordingly, chemosensory modulation of LHRH neuronal activity and mating behavior are dramatica

206 rast to established notions on the nature of LHRH neuronal inputs, our data identify major olfactory

207 migration, resulting in an excess number of LHRH cells in the accessory olfactory bulb, was observed

208 Fewer than the normal number of LHRH neurons are found in the basal forebrain, and many

209 s olfactory axon outgrowth and the number of LHRH neurons that migrate out of the nasal tissue.

210 placode and the ventral migratory pathway of LHRH neurons from rhesus monkey embryos at embryonic age

211 tivated LHRH neurons, with the percentage of LHRH+/c-Fos+ double-labeled cells approximately fivefold

212 A plot of LHRH mRNA level per cell versus DRB treatment time showe

213 tectable response of the cytoplasmic pool of LHRH mRNA to changes in gene transcription at this time.

214 he caudal vomeronasal nerve and positions of LHRH neurons are abnormal.

215 ium did not block Mn2+-stimulated release of LHRH, even with the higher dose of MnCl2.

216 one secretion, caused by impaired release of LHRH, the hypothalamic neuropeptide that controls sexual

217 of the LH surge and in the replenishment of LHRH stores depleted during the surge.

218 ODQ blocked the Mn2+-stimulated secretion of LHRH in a dose-dependent manner, indicating that GC is t

219 rnating left- and right-sided stimulation of LHRH neurons; under such circumstances, the functional a

220 rbB-dependent, glia-mediated, stimulation of LHRH release.

221 hours encompassing the preovulatory surge of LHRH.

222 t not always Decapeptyl, paralleled those of LHRH-R protein.

223 t GABA participates in appropriate timing of LHRH neuronal migration into the developing brain.

224 The results showed that the use of LHRH peptide as a targeting moiety in the anticancer DDS

225 nhibitory and stimulatory effects of GABA on LHRH neurons.

226 we evaluated the role of GABAergic input on LHRH neuronal migration using olfactory explants, previo

227 the effect of GABAA receptor stimulation on LHRH and/or gonadotropin release in prepubertal animals,

228 the functional impact of NPY-IR terminals on LHRH-IR neurons.

229 in the vomeronasal organ anlage that turn on LHRH gene and peptide expression subsequently migrate in

230 sence of E and P and activate either AVPV or LHRH neurons.

231 st Decapeptyl (25 microg/day) for 30 days or LHRH antagonist Cetrorelix pamoate (100 microg/day) for

232 eripherin-immunoreactive olfactory fibers or LHRH cell number.

233 e of gonadotropin-releasing hormone (GnRH or LHRH), is the active pharmaceutical ingredient used to t

234 dotropin hormone releasing hormone (GnRH, or LHRH) neurons in the rostral medial preoptic region of t

235 f LHRH-conjugated drugs (LHRH-prodigiosin or LHRH-paclitaxel) into groups of 4-week-old athymic femal

236 and paclitaxel (PTX) drugs and overexpressed LHRH receptors on the breast cancer cells and tumors.

237 Our results show that overexpressed LHRH receptors serve as binding sites on the breast canc

238 cancer cell line (A2780) that overexpresses LHRH receptors and exhibit high toxicity to these tumor

239 gated drug-loaded microspheres (PLGA-PEG_PGS-LHRH, PLGA-PEG_PTX-LHRH) is shown to result in greater r

240 icrospheres (PLGA-PEG_PGS-LHRH, PLGA-PEG_PTX-LHRH) is shown to result in greater reductions of cell/t

241 Pituitary LHRH-R mRNA and LHRH-R protein levels were not significa

242 rum LH and testosterone levels and pituitary LHRH-R in male rats are also decreased by high doses of

243 days on the expression of mRNA for pituitary LHRH receptor (LHRH-R) and the levels of LHRH-R protein

244 effect of Cetrorelix on serum LH, pituitary LHRH-R mRNA, and LHRH-R protein was greater than that of

245 esterone, and the concentration of pituitary LHRH receptors (LHRH-Rs) and their mRNA expression.

246 ix, inhibit the gene expression of pituitary LHRH-R indirectly, by counteracting the stimulatory effe

247 in vitro on the expression of the pituitary LHRH-R gene and its ability to counteract the exogenous

248 generating cGMP and resulting in prepubertal LHRH release.

249 roscopy revealed that subsets of prepubertal LHRH neurons are endowed with alpha 1, alpha 2, beta 2/3

250 These data indicate that, in primary LHRH neurons, LHRH mRNA has an intrinsically high rate o

251 een of migrating versus nonmigrating primary LHRH neurons.

252 cotinic acetylcholine receptors and produced LHRH release via a mechanism that is different from the

253 f LH responses in female rats, while raising LHRH-R mRNA expression in female rats by 23% and LHRH-R

254 ression of mRNA for pituitary LHRH receptor (LHRH-R) and the levels of LHRH-R protein were evaluated

255 ary gonadotroph functions and LHRH-receptor (LHRH-R) expression are incompletely understood.

256 e concentration of pituitary LHRH receptors (LHRH-Rs) and their mRNA expression.

257 Decapeptyl microcapsules reduced LHRH-R mRNA expression in male pituitaries to 58% on day

258 l cell type of the median eminence, regulate LHRH release during the estrous cycle by undergoing plas

259 Relative LHRH mRNA content per cell was quantitated by single-cel

260 releasing hormone (LHRH) neurons to secrete LHRH, the neuropeptide controlling sexual development.

261 The hazard ratio showed LHRH agonists to be essentially equivalent to orchiectom

262 Both 50 and 250 microM MnCl2 stimulated LHRH release (P < 0.05 and P < 0.01, respectively).

263 ess the effect of the blockers on stimulated LHRH secretion.

264 Such LHRH cells expressed nestin mRNA but not Mash-1 mRNA and

265 Our results confirm that LHRH antagonists, such as cetrorelix, inhibit the gene e

266 al studies in rodents have demonstrated that LHRH neurons are innervated by GABA-containing processes

267 The results indicate that LHRH neurons derived from the monkey olfactory placode p

268 Analysis of covariance showed that LHRH-agonist treatment resulted in an increase of 0.6 (9

269 y GABA-containing processes, suggesting that LHRH secretion is under direct transsynaptic GABAergic c

270 The LHRH receptor targeting DDS did not show in vivo pituita

271 The LHRH-IR perikarya were located mainly in the preopticose

272 of difference in overall survival among the LHRH agonists, although CIs were wider for leuprolide (h

273 hows a difference in effectiveness among the LHRH agonists.

274 tes on the breast cancer cells/tumor and the LHRH-conjugated drugs inhibited the growth of breast cel

275 tion of treatment was 3.5+/-0.9 years in the LHRH-agonist group and 2.1+/-1.2 years in the placebo gr

276 The principal adverse event in the LHRH-agonist group was decreased accretion of bone miner

277 or 0.1 nM triptorelin for 5 h increased the LHRH-R mRNA level by 77-88%.

278 tively allow or prevent direct access of the LHRH nerve terminals to the portal vasculature.

279 nhibited the migration of nearly half of the LHRH neuron population, without affecting the VNN tract

280 tration of cetrorelix and triptorelin on the LHRH-R mRNA level and gonadotropin secretion in ovariect

281 le rats, cetrorelix treatment suppressed the LHRH-R mRNA level by 33%, but triptorelin increased it b

282 ructural analysis would demonstrate that the LHRH system in the human hypothalamus is regulated by NP

283 viewed in relation to circulating LH titers, LHRH primary transcript levels were high prior to the st

284 Further visualization of afferents to LHRH neurons across the brain offers a unique opportunit

285 (LHRH), AN-207, binds with high affinity to LHRH receptors and can be targeted to tumors expressing

286 tification of neuronal networks connected to LHRH neurons.

287 tatory transsynaptic and astroglial input to LHRH neurons during sexual development.

288 caused by changes in trans-synaptic input to LHRH neurons.

289 ) was used as a targeting moiety (ligand) to LHRH receptors that are overexpressed in the plasma memb

290 together, there was no additive response to LHRH and the response was the same as to either compound

291 sed as the only systemic adjuvant treatment, LHRH agonists did not significantly reduce recurrence (2

292 an LH surge in response to E + P treatment, LHRH and AVPV neurons in males failed to show increased

293 ne-releasing hormone (LHRH) agonist, [D-Trp6]LHRH.

294 65% on days 10 and 30, respectively, whereas LHRH-R protein was 64% of control on day 10 and returned

295 nist increases adult height in children with LHRH-dependent precocious puberty and is prescribed by s

296 arged prostates alone or in combination with LHRH antagonists.

297 wed NPY-IR axon varicosities in contact with LHRH-IR perikarya and main dendrites.

298 In 17 of 20 cultures with LHRH-positive cells, [Ca(2+)](i) oscillations occurred s

299 reatment withdrawals were less frequent with LHRH agonists (0% to 4%) than with nonsteroidal antiandr

300 ond to stimulation of AMPARs and mGluRs with LHRH release, and this response is prevented by blocking